2021
The Prognostic Association of Prostate MRI PI-RADS™ v2 Assessment Category and Risk of Biochemical Recurrence after Definitive Local Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis
Rajwa P, Mori K, Huebner NA, Martin DT, Sprenkle PC, Weinreb JC, Ploussard G, Pradere B, Shariat SF, Leapman MS. The Prognostic Association of Prostate MRI PI-RADS™ v2 Assessment Category and Risk of Biochemical Recurrence after Definitive Local Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis. Journal Of Urology 2021, 206: 507-516. PMID: 33904755, DOI: 10.1097/ju.0000000000001821.Peer-Reviewed Original ResearchConceptsRisk of BCRPI-RADS v2 scoreDefinitive local therapyBiochemical recurrencePrognostic significanceRadical prostatectomyProstate cancerV2 scoreLocal therapySystematic reviewMagnetic resonance imaging (MRI) classificationPrimary definitive treatmentIndependent prognostic significanceRisk of biasSignificant prostate cancerProstate Imaging ReportingPI-RADS v2Prostate cancer diagnosisWeb of ScienceReliable diagnostic toolOncologic outcomesDefinitive treatmentMRI findingsPI-RADSPrognostic association
2020
Initial Evaluation of Rapid, Direct-to-Digital Prostate Biopsy Pathology.
Torres R, Olson E, Homer R, Martin DT, Levene MJ, Perincheri S, Sprenkle PC, Humphrey PA. Initial Evaluation of Rapid, Direct-to-Digital Prostate Biopsy Pathology. Archives Of Pathology & Laboratory Medicine 2020, 145: 583-591. PMID: 32991670, DOI: 10.5858/arpa.2020-0037-oa.Peer-Reviewed Original Research
2015
Effect of Silodosin, an Alpha1A-Adrenoceptor Antagonist, on Ventral Prostatic Hyperplasia in the Spontaneously Hypertensive Rat
Shimizu S, Shimizu T, Tsounapi P, Higashi Y, Martin DT, Nakamura K, Honda M, Inoue K, Saito M. Effect of Silodosin, an Alpha1A-Adrenoceptor Antagonist, on Ventral Prostatic Hyperplasia in the Spontaneously Hypertensive Rat. PLOS ONE 2015, 10: e0133798. PMID: 26308715, PMCID: PMC4550428, DOI: 10.1371/journal.pone.0133798.Peer-Reviewed Original ResearchMeSH KeywordsActinsAdrenergic alpha-1 Receptor AntagonistsAnimalsChemokine CXCL1Fibroblast Growth Factor 2IndolesInterleukin-6MaleMalondialdehydeProstateProstatic HyperplasiaRatsRats, Inbred SHRReceptors, Adrenergic, alpha-1Regional Blood FlowTransforming Growth Factor beta1Tumor Necrosis Factor-alphaConceptsProstatic blood flowEffects of silodosinBasic fibroblast growth factorAlpha1A-adrenoceptor antagonistInterleukin-6Blood flowBlood pressureProstatic hyperplasiaHypertensive ratsTissue levelsWKY ratsΑ-SMATGF-β1Twelve-week-old male SHRsVentral prostateCytokine-induced neutrophil chemoattractant-1Selective alpha1A-adrenoceptor antagonistAlpha-smooth muscle actinGrowth factor beta 1Neutrophil chemoattractant-1Spontaneously Hypertensive RatsBenign prostatic enlargementBody weight ratioWistar-Kyoto ratsMorphological abnormalitiesProtective effect of hydroxyfasudil, a Rho kinase inhibitor, on ventral prostatic hyperplasia in the spontaneously hypertensive rat
Holmström F, Shimizu S, Shimizu T, Higashi Y, Martin DT, Honda M, Saito M. Protective effect of hydroxyfasudil, a Rho kinase inhibitor, on ventral prostatic hyperplasia in the spontaneously hypertensive rat. The Prostate 2015, 75: 1774-1782. PMID: 26286428, DOI: 10.1002/pros.23063.Peer-Reviewed Original ResearchConceptsVentral prostateBlood pressureHypertensive ratsWKY ratsInflammatory cytokinesProstatic hyperplasiaIL-6Growth factorΑ-SMATGF-β1Twelve-week-old SHRMorphological abnormalitiesROCK activityTail-cuff methodBody weight ratioWistar-Kyoto ratsHypertensive rat modelSmooth muscle contractionRho-kinase pathwayWeeks of ageRho-kinase inhibitorSmooth muscle differentiation markersInflammatory markersChronic treatmentProstate weight